Source: FIRSTWORD PHARMA

Glaukos: Glaukos Corporation Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2027 (the “notes”) in a private offering. The notes will be offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Glaukos expects to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of the notes.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Thomas W Burns's photo - President & CEO of Glaukos Corp

President & CEO

Thomas W Burns

CEO Approval Rating

88/100

Glaukos is an ophthalmic medical device firm that creates micro invasive glaucoma surgery options for patients. Read more